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Abstract 
Enzymes are one of the most important groups of drug targets, and identifying possible ligand-enzyme interactions is 
of major importance in many drug discovery processes. Novel computational methods have been developed that can 
apply the information from the increasing number of resolved and available ligand-enzyme complexes to model new 
unknown interactions and therefore contribute to answer open questions in the field of drug discovery like the identifi-
cation of unknown protein functions, off-target binding, ligand 3D homology modeling and induced-fit simulations.
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Background
Predicting ligands that bind with sufficient strength to a 
corresponding protein is a challenging task in biochem-
istry and has significant implication in the discovery of 
new drug candidates. Many approaches have been devel-
oped for this task; the most commonly used being molec-
ular docking [1]. However one of the main drawbacks of 
classical template-free docking is that every molecule is 
docked ab initio, and no information from existing simi-
lar protein–ligand complexes is taken into consideration. 
Therefore alternative approaches that use information 
from existing protein–ligand complexes, which can be 
obtained from freely-available databases, such as the Pro-
tein Data Bank [2] are becoming increasingly important. 
The main assumption of such approaches is that simi-
lar protein binding sites bind similar ligands, and thus a 
known ligand from one protein can be transposed to a 
similar binding site in another protein that was previously 
not known to bind this ligand. Transposition of ligands 
is based on accurate alignments of three-dimensional 
amino-acid patterns or of their corresponding functional 
groups in the proteins’ binding sites; due to their local 
nature in the binding sites, such alignments may not be 
possible with standard sequence or structure alignment 
approaches. Ligand transposition shown in Fig.  1 can 
thus be a powerful approach, which can be used in phar-
maceutical applications such as drug repositioning [3–6], 
ligand-homology modeling [7–9], induced-fit simulation 
[10] and binding site prediction [11–13]. Information 
about the software described in the following sections is 
available in Table 1.
Function prediction
Proteins interact with one another and with other mole-
cules, mediate metabolic and signaling pathways and thus 
regulate cellular processes [14]. One of the fundamental 
tasks of proteins is to act as enzymes [15], i.e., biological 
catalysts that increase the rate of practically all chemical 
reactions that are taking place within cells. Due to their 
central role in biological function, they control mecha-
nisms leading to healthy and diseased states in the organ-
ism. However, for a substantial number of proteins, and 
subsequently enzymes, their functions are not known, 
therefore an important challenge in structural genom-
ics is the prediction of function of these uncharacterized 
proteins [16]. While experimental determination of a 
protein function is still the most reliable way to charac-
terize unknown proteins, it is difficult to prioritize func-
tional experiments among the many possible functions a 
protein could perform. To guide experimentalist, a num-
ber of computer approaches are routinely used to predict 
protein function. However, many are based on sequence 
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and overall structural homology [17, 18], consequently 
often missing similarities when only local binding sites 
are conserved. The identification of such binding sites 
on the protein surface is therefore usually the starting 
point for protein function annotation. Moreover, because 
knowledge of the binding site location is the prerequisite 
for molecular docking, binding site identification is often 
a first step in structure-based drug design.
Based on the idea that proteins with similar local bind-
ing sites perform similar function, an algorithm ProBiS 
and its corresponding web server [19, 20] was developed. 
ProBiS uses a fast maximum clique algorithm [21] to 
compare a query protein to members of a database of 3D 
protein structures and detects with sub-residue precision 
structurally similar binding sites as patterns of physio-
chemical properties on the protein surface. The algorithm 
thus identifies database proteins that share local struc-
tural similarities with the query protein independent of 
the global protein folds, and generates structure-based 
alignments for every query protein-database protein pair. 
Moreover, structural similarity scores are calculated for 
the query protein surface residues, and are expressed as 
different colors on the protein’s surface. ProBiS was tested 
for its binding site detection ability on a set of 39 protein 
structures and by comparing it to an evolutionary con-
servation mapping method ConSurf [22] and an energy-
based method Q-SiteFinder [23], it was shown that 
ProBiS outperformed both of the two aforementioned 
methods. Moreover, to demonstrate ProBiS’ unique abil-
ity to detect and align similar binding sites in the absence 
of global fold similarity, the authors examined 10 pairs of 
protein structures, where the two members of each pair 
Fig. 1 Flowchart of binding site comparison with subsequent ligand transposition
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exhibited different folds but had known similar binding 
sites and performed a similar function. ProBiS was com-
pared to three different structural alignment algorithms; 
DaliLite [24], MolLoc [25] and MultiBind [26]. The com-
parison between the methods was made by calculating 
the RMSD between previously identified, similar bind-
ing site residues, after the proteins in the pair have been 
superimposed. ProBiS demonstrated, by far, the lowest 
average RMSD in comparison to other methods; while 
also having the ability to align binding sites in an unsu-
pervised fashion, which allows it to perform automatic, 
large database searches. ProBiS, in combination with 
molecular dynamics, was also used to propose the func-
tion to a protein of unknown activity—the Tm1631 pro-
tein from T. maritima [27]. The binding site comparison 
revealed numerous similarities with nucleotide binding 
sites; including specifically, a DNA-binding site of endo-
nuclease IV. Based on the superimposition of Tm1631 
with endonuclease IV, a hypothetical model of the 
Tm1631-DNA complex was constructed. This model was 
validated with the use of CHARMM [28, 29] to perform 
a molecular dynamics simulation, which showed that the 
interactions predicted by the Tm1631-DNA model cor-
respond well to those known to be importation in the 
endonuclease IV-DNA complex. The simulation also 
showed that the binding free energies of the model and 
the known complex were in close agreement. The authors 
thus concluded that the Tm1631 protein could be a DNA 
binding enzyme with endonuclease activity. ProBiS was 
also used to identify conserved binding sites on hemag-
glutinin, a protein responsible for binding the influenza 
virus to cells [30]. A local structural superimposition 
across all subtypes and strains of hemagglutinin available 
in the PDB at the time, revealed a new conserved region 
on hemagglutinin, a potential conserved target for influ-
enza drug and vaccine development.
Another freely-accessible web server for binding site 
annotation—GalaxySite [31] combines binding site infor-
mation from known proteins with molecular docking to 
predict ligand binding amino acid residues. Initially the 
server uses HHsearch [32] to search for similar protein–
ligand complexes in the structural databases. The high-
est ranking ligands are transposed from the target to the 
query structure where their binding conformation is opti-
mized using the LigDockCSA protein–ligand docking 
program [33]. Binding-site residues are then identified 
based on their proximity to the docked ligand. GalaxySite 
was extensively tested on different ligand binding predic-
tion test sets, on which it showed superior or similar per-
formance compared to other state of the art prediction 
methods.
Moreover, Surflex-PSIM [34], a novel method combin-
ing initial binding site recognition with subsequent bind-
ing site comparisons has been developed. The newest 
version of Surflex-PSIM is able to automatically detect 
ligand binding pockets and compare them, based on 
their surface similarity to other binding sites extracted 
from large protein databases (e.g. PDB). The method 
was tested on a set of eight proteins, whose function was 
unknown at the time of the testing. All of the eight pro-
teins were screened against ~60,000 ligand binding sites 
from the PDB. Surflex-PSIM correctly identified func-
tional matches that predated query protein biochemical 
annotation for five out of the eight proteins. In addition, 
Table 1 Software packages for modeling protein–ligand binding using ligand transposition
Name URL Description Availability
ProBiS http://www.probis.cmm.ki.si/ Detects structurally similar binding sites 
without reference to known binding sites
Freely-accessible web server
GalaxySite http://www.galaxy.seoklab.org/site/ Combines binding site information from 
known proteins with molecular docking 
to predict ligand binding amino acid 
residues
Freely-accessible web server
Surflex-PSIM http://www.biopharmics.com/downloads.html Fully automated ligand binding pocket 
detection and comparison based on sur-
face similarities to other known proteins
Not freely-accessible
POP https://www.sites.google.com/site/offtargetpipeline/ Integrated computational method for 
proteome-wide off target identification
Free for academic users and 
not-for-profit institutions
FINDSITEcomb http://www.cssb.biology.gatech.edu/FINDSITE-COMB/ Threading/structure-based, proteomic-
scale virtual ligand screening approach
Freely-accessible for web server 
for academic users
ProBiS-ligands http://www.probis.cmm.ki.si/ligands/ Detects and transposes ligands between 
similar binding sites
Freely-accessible web server
FragFEATURE https://simtk.org/home/frag-feature/ A machine learning approach to predict 
small molecules fragments preferred by 
a target
Freely-accessible
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12 currently unannotated proteins were also screened, 
resulting in a large number of statistically significant 
binding site matches, which could suggest likely func-
tions for these uncharacterized proteins. Surflex-PSIM 
was also used as a part of a combined computational 
approach which identified known PPARα agonists as 
also being cyclooxygenase (COX) inhibitors [35]. Pock-
ets of 9 COX enzymes were compared to 14 human 
PPARα binding pockets and the method identified high 
similarity of pocket surfaces between proteins with the 
PDB codes 2rew (PPARα receptor) and 3rr3 (COX-2 
enzyme). Subsequent experiments confirmed that fenofi-
bric acid, a known PPARα agonist, does in fact inhibit, in 
a does dependent manner, both the COX-1 and COX-2 
enzymes.
Drug repositioning
Drug repositioning or repurposing is a principle of dis-
covering novel therapeutic indications for existing 
approved drugs, which provides an alternative and cost-
efficient strategy of discovering disease therapeutics [36]. 
A prerequisite for drug repurposing is drug promiscu-
ity (polypharmacology), which is a drug’s ability to bind 
to several different targets. A recent study suggests that 
the most important factor contributing to the observed 
promiscuity of many drugs is the local binding site simi-
larities between different protein targets [3]. It was dis-
covered that off-target binding is the major cause of 
unwanted side-effects for many drugs from a wide range 
of therapeutic areas [37]. Therefore binding site compari-
son methods may have an important role in identifying 
the polypharmacological activity of molecules.
Recently, an integrated computational method for pro-
teome-wide off target identification, abbreviated POP 
(proteome-wide off-target pipeline) was developed. POP 
combines ligand binding site comparison analysis, pro-
tein–ligand docking and electrostatic potential calcula-
tion to identify possible promiscuous protein–ligand 
interactions throughout the proteasome. The core com-
ponent of this method is the well-established software for 
binding site comparison SMAP [38, 39]. SMAP initially 
detects the location and boundary of the query protein 
ligand binding site. The binding site is then compared 
against target 3D protein structures using a sequence-
order independent profile–profile alignment (SOIPPA) 
algorithm [39] that is able to detect similar binding sites 
between structurally unrelated proteins. The next step is 
the superimposition (and subsequent ligand transposi-
tion) of the query binding site to the top scoring target 
binding sites. The transposed ligand binding pose serves 
as the starting structure in the following docking and 
scoring. The highest scoring protein–ligand complexes 
reflect the possible off-targets of the ligand. In addition, 
the electrostatic potential binding energy and similarity 
between the binding sites can be calculated based on the 
binding pose of the ligand. POP was applied to identify 
possible off-targets of the HIV protease inhibitor nelfina-
vir. The protein–ligand complex of HIV protease bound 
with nelfinavir (PDB code: 1ohr) was searched against 
a variety of human protein structures and models. Top 
ranked hits contained multiple members of the protein 
kinase superfamily, most of which are on the upstream 
of the Akt1 and Akt2 enzymes in the AKT pathway [40], 
which is in correlation with the experimentally observed 
anti-cancer effect of nelfinavir.
Ligand 3D homology modeling
Virtual screening is a widely used approach in the early 
stage of pharmaceutical discovery [41]. In practice, we 
distinguish two broad categories of virtual screenings: 
(a) ligand based and (b) structure based [42, 43]. Ligand 
based virtual screening is relatively fast, however the 
method requires previously known ligands that bind to a 
certain target; this hinders its universality and large-scale 
application. On the other hand, structure based virtual 
screening uses the structure of a target/target binding 
site, to which it docks potential drug molecules and eval-
uates the binding likelihood using different scoring func-
tions; its main advantage is that no prior knowledge of 
known active ligands is needed. The main disadvantage 
of structure based virtual screening is the requirement 
for high-resolution structures of target proteins, which 
are in many cases not available, especially for G-protein 
coupled receptors and ion-channels [44]. However, with 
increasing number of holo protein structures deposited 
in large protein databases, a novel type of virtual screen-
ing, termed ligand-homology modeling (LHM) is gain-
ing recognition [7–9, 45]. LHM is a knowledge-based 
approach that relies on the fact that evolutionary related 
proteins share similar functions and thus bind similar 
ligands, and that this information can be used to predict 
ligand-target interactions. In general, LHM algorithms 
start with identifying and aligning similar binding sites 
between a query and target database holo proteins, which 
is then followed by transposing the ligands from target 
proteins to the query binding site.
One of the main shortcomings of the LHM is the need 
for sufficient numbers of holo proteins that share simi-
lar binding sites to the query protein. To overcome this 
serious disadvantage, a novel combined ligand homol-
ogy modeling approach, FINDSITEcomb was developed 
[46, 47]. FINDSITEcomb is a composite approach consist-
ing of the FINDSITEfilt and the FINSDSITEX algorithms. 
While the former still uses known holo proteins depos-
ited in protein databases, FINSDSITEX circumvents this 
requirement by employing homology modeling to model 
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structures of target proteins not yet available in protein 
databases. The FINDSITEfilt algorithm works by initially 
finding template holo protein structures that are evo-
lutionary related to the target structure from the PDB 
database. Next, a heuristic structure–pocket alignment 
method is used to superimpose template pockets to the 
target structure and a sequence dependent scoring func-
tion to rank the best templates (based on the structure-
pocket alignment) from whose their corresponding 
ligands will be used as reference small molecules in sub-
sequent ligand based virtual screening. FINDSITEX on 
the other hand, as mentioned, employs homology mod-
eling methods to model structures of template proteins, 
which are then aligned and compared to target proteins 
using a global structure alignment method. Similar as in 
FINDSITEfilt, the ligands of the top ranked templates are 
used as reference small molecules for ligand based vir-
tual screening, where the appropriate template ligands 
are obtained from the DrugBank [48] and ChEMBL [49] 
databases. By combining the scores obtained from FIND-
SITEfilt and FINDSITEX ligand based virtual screening 
runs, the method evaluates the likelihood of each com-
pound of being a true active. The performance of FIND-
SITEcomb was thoroughly evaluated both on the directory 
of useful decoys (DUD) database [50] and experimen-
tally on eight different protein targets [51]. In the former 
evaluation, FINDSITEcomb outperformed, in most cases, 
established docking methods, such as AUTODOCK 
Vina [52] and DOCK 6 [53]; demonstrating significantly 
higher enrichment factors and areas under the ROC 
curves. Testing FINDSITEcomb on eight different proteins 
with subsequent experimental ligand binding evalua-
tions, the authors identified 47, mostly novel small mol-
ecules with µM or better affinities. Of those, 10 ligands 
showed affinities in the nanomolar range (for dihydrop-
holate reductase from E.coli and two mammalian protein 
tyrosine phosphatases).
Also a recently developed, freely-available web server, 
which enables ligand homology modeling, is ProBiS-
ligands (Fig.  2) [45], a method that uses a fast maxi-
mum clique algorithm [21] to screen the non-redundant 
PDB database, to find structurally similar target binding 
sites to user provided input query protein, independ-
ent of their sequence or global structural similarity. 
Ligands which are bound in the identified similar bind-
ing sites are transposed to the query protein by rotation 
and translation of their atoms’ coordinates generated by 
the superimposition matrices acquired from the initial 
superposition of the query and target proteins. ProBiS-
ligands is able to predict protein–protein, protein-small 
molecules, protein-nucleic acid, and protein-ion interac-
tions. The performance of the web server was assessed 
with a test set [54] containing 500 proteins models and 
their corresponding experimental structures. The success 
of ligand prediction was measured by calculating the cor-
respondence between the predicted ligand binding sites, 
i.e. query residues <4 Å from the first cluster of predicted 
small molecules or ions and the actual known binding 
sites for each of the 500 proteins. This binding site pre-
diction results were evaluated with the Matthews cor-
relation coefficient, precision and recall (for definitions 
of each see, e.g. [54]). Moreover to assess the similarity 
of predicted ligands with the actual ones, each highest 
scoring (by Z-score) predicted ligand from the first small 
molecule or ion cluster was compared with the actual 
known ligands using an in-house developed 2D molecu-
lar graph matching algorithm. Ligand similarities were 
expressed as the Tanimoto coefficients and were averaged 
across all comparisons. ProBiS-ligands showed encour-
aging results, with the average ligand similarity Tanimoto 
coefficient of 0.61 (0.55) and MCC of 0.54 (0.41) (the val-
ues in parenthesis are for the modeled structure). Even 
when all templates sharing >10 % sequence identity with 
the target were removed (to simulate the lack of similar 
templates that frequently occur in real world simula-
tions), reasonable predictions for the experimental pro-
tein structures were still possible with the average ligand 
similarity of 0.40 and MCC of 0.28. In contrary, for pro-
tein models, templates of at least 20-30 % sequence iden-
tity were required to obtain similar accuracy.
As discussed, an important drawback in classical 
screening methods is that large molecular databases 
(usually containing millions of compounds) have to be 
screened to find potential drug candidates. Given this 
difficulty of thoroughly exploring the chemical-space of 
drug like molecules, fragment-based approaches have 
emerged. Fragments refer to low-molecular-weight mol-
ecules, usually 140–300 Daltons in weight [55, 56], that 
can be connected to form larger molecules. It was shown 
that fragments have higher hit rates compared to large, 
complex drug-like molecules because they are less likely 
to possess suboptimal interactions or physical clashes 
with the target [57]. Moreover, a fragment library can 
provide a more compact and tractable basis set for chem-
ical space than standard small molecule libraries [58]. A 
novel knowledge-based fragment binding predictor Frag-
FEATURE was developed that overcomes many limita-
tions of the existing fragment binding predictors [59]. 
Using information from the PDB, the authors prelimi-
narily created a database linking local protein structural 
environments to the small molecule fragments they bind. 
Given the structural environments from a target protein, 
FragFEATURE compares them to the database to find 
similar structural environments and identifies statisti-
cally preferred fragments. The results demonstrated the 
method’s ability to rediscover fragments corresponding 
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to the ligands bound with 74 % precision and 82 % recalls 
on average. For many protein targets, FragFEATURE was 
able to identify high scoring fragments that are substruc-
tures to known inhibitors. Such predicted fragments can 
serve as inputs to fragment-based drug design or serve as 
refinement criteria for creating target-specific compound 
libraries for experimental or computational screening.
Induced‑fit simulation
One of the main downsides of many established molec-
ular docking algorithms is their inability to consider 
binding site flexibility [60]. This can present a serious 
drawback, especially when only a crystal structure with-
out its corresponding ligands (apo structure) is available. 
Such a protein can be locked in a conformation that is a 
poor representation of an actual spatial arrangement of 
binding site amino acid residues upon ligand binding 
[61], making it a poor candidate for target based virtual 
screening studies.
To overcome difficulties where the binding pocket 
conformation is unsuitable for docking, our group devel-
oped a new simple and fast approach to simulate the 
induced-fit conformational changes of protein structures 
upon binding. For example, the UDP-N-acetylglucosa-
mine enolpyruvyl transferase enzyle enzyme (MurA, 
PDB code: 1uae) from E. coli exists in the PDB only as 
apoprotein and our initial docking study with the dock-
ing program FRED software [62] showed that most drug-
like molecules were unable to dock in this binding site 
without exhibiting severe clashes with the amino acid 
residues. To circumvent this problem, ProBiS-ligands 
[45] was used in combination with standard molecular 
minimization algorithms. With the E. coli MurA crystal 
structural as input, ProBiS-ligands enabled the identi-
fication and transposition of a ligand (PDB ligand code: 
TAV) bound originally in a binding site of the MurA 
enzyme from E. cloace (PDB code: 1ybg). With the new-
found ligand transposed to the query binding site and 
all the original ligands and water molecules removed, 
molecular minimization was performed on this complex 
to obtain an open binding site structure of the enzyme 
that was more suitable for docking. The docking was 
then repeated on this opened binding site against the 
ZINC Drugs Now database [63], which yielded very 
Fig. 2 Ligand homology modeling using ProBiS-ligands web server on the example of butyrylcholinesterase enzyme (PDB code: 4tpk). On the right 
side of the screen is the list of predicted ligands with their corresponding Z-scores, specificities and PDB codes of protein structures from which they 
were transposed. The selected ligand’s row is highlighted orange. On the left side is the Jsmol viewer that contains the three-dimensional pose of the 
selected predicted ligand (galantamine, sticks, violet) and the predicted binding amino-acid residues (sticks, CPK colors, black labels)
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good inhibitors of MurA enzyme as three of the high-
est scoring compounds that were biochemically tested 
for their inhibitory ability showed lower than 1 µM IC50 
values and are now subject for further optimization and 
research (in preparation).
Conclusion
Ever increasing numbers of 3D holo enzyme structures 
deposited in large protein databases enable that the infor-
mation of known enzyme-ligand interactions be used in 
predicting and evaluating novel complexes—a key step in 
drug discovery. Knowledge-based computational meth-
ods that apply this information have been successfully 
used in a wide variety of fields that are of interest to phar-
maceutical research; from drug repositioning to simulat-
ing induced-fit upon ligand binding. Increased usage of 
knowledge-based methods for modeling ligand-enzyme 
interactions is expected in the near future, especially in 
the early stages of drug discovery processes.
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